- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01253564
A Study of RO5185426 in Previously Treated Melanoma Patients With Brain Metastases
June 26, 2017 updated by: Hoffmann-La Roche
An Open-label, Pilot Study of RO5185426 in Previously Treated Metastatic Melanoma Patients With Brain Metastases
This open-label study will assess the safety and efficacy of RO5185426 in previously treated metastatic melanoma patients with brain metastases.
Patients will receive RO5185426 at a dose of 960 mg twice daily orally until disease progression or unacceptable toxicity occurs.
Study Overview
Study Type
Interventional
Enrollment (Actual)
24
Phase
- Phase 2
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Lausanne, Switzerland, 1011
- CHUV; Departement d'Oncologie
-
Zürich, Switzerland, 8091
- Universitätsspital Zürich; Dermatologische Klinik
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Adult patients, >/= 18 years of age
- Metastatic melanoma (Stage IV, American Joint Committee on Cancer) with BRAF mutation (cobas 4800 BRAF V600 Mutation Test)
- Brain metastases for which surgical resection is not a treatment option
- Patients must have failed at least one previous treatment for brain metastases
- Requiring corticosteroids for symptom control
- Eastern Cooperative Oncology Group (ECOG) performance status 0-2
Exclusion Criteria:
- Increasing corticosteroid dose during the 7 days prior to study entry
- Previous malignancy within the past 2 years, except for basal or squamous cell carcinoma of the skin or carcinoma in-situ of the cervix
- Concurrent administration of any anticancer therapies other than those administered in the study
- Clinically significant cardiovascular disease or event within the 6 months prior to first dose of study drug
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Single Arm
|
960 mg b.i.d. orally
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With Adverse Events (AEs)
Time Frame: From baseline up to last dose (0.1 to 11.3 months) plus 28 days
|
AE:any unfavorable and unintended sign, symptom, or disease associated with use of study drug, regardless of relation to study drug.
Pre-existing conditions that worsened and laboratory or clinical tests that resulted in change in treatment or discontinuation from study drug were reported as AEs.
Serious AE: resulted in death, life-threatening, required in-patient hospitalization or prolongation of existing hospitalization, resulted in persistent or significant disability/incapacity, was congenital anomaly/birth defect or was medically significant.
Grade-1:discomfort but no disruption of normal daily activity.
Grade-2:discomfort sufficient to reduce or affect daily activity,no intervention indicated.Grade-3:inability to perform normal daily activity,intervention indicated.Grade-4:immediate threat to life or leading to permanent mental or physical condition that prevented performing normal daily activities.Grade 5: death.
Any AE included participants with serious and non-serious AE.
|
From baseline up to last dose (0.1 to 11.3 months) plus 28 days
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percentage of Participants With a Best Overall Response of Complete Response (CR) or Partial Response (PR) by Disease Site
Time Frame: Baseline, Week 4, Week 8 and thereafter every 8th week until progressive disease, unacceptable toxicity, consent withdrawal, death or other reasons deemed by the investigator (up to 16 months)
|
Objective response was assessed by the investigator according to Response Evaluation Criteria in Solid Tumours (RECIST) (Version 1.1).
CR was defined as disappearance of all target and non-target lesions and no new lesions.
PR was defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters), no progression in non-target lesions, and no new lesions.
Best overall response was calculated separately for brain, other sites (extracranial) and whole body.
Percentage of participants with 95 percent (%) Clopper-Pearson confidence interval (CI) are reported.
|
Baseline, Week 4, Week 8 and thereafter every 8th week until progressive disease, unacceptable toxicity, consent withdrawal, death or other reasons deemed by the investigator (up to 16 months)
|
Duration of Response by Disease Site
Time Frame: Baseline, Week 4, Week 8 and thereafter every 8th week until progressive disease or death (up to 16 months)
|
Duration of response was defined as the time interval between the date of the earliest qualifying response and the date of progressive disease (PD) or death, only for those participants whose best overall response was CR or PR.
CR and PR were assessed by investigator according to RECIST version 1.1.
CR was defined as disappearance of all target and non-target lesions and no new lesions.
PR was defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters), no progression in non-target lesions, and no new lesions.
PD was defined as at least 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 millimeter (mm), progression of existing non-target lesions, or presence of new lesions.
Duration of response was calculated by Kaplan-Meier estimates separately for brain, other sites (extracranial) and whole body.
|
Baseline, Week 4, Week 8 and thereafter every 8th week until progressive disease or death (up to 16 months)
|
Time to Response by Disease Site
Time Frame: Baseline, Week 4, Week 8 and thereafter every 8th week until progressive disease, unacceptable toxicity, consent withdrawal, death or other reasons deemed by the investigator (up to 16 months)
|
Time to response was defined as the interval between the date of first treatment and the date of first documentation of CR or PR (whichever occurred first).
CR and PR were assessed by investigator according to RECIST version 1.1.
CR was defined as disappearance of all target and non-target lesions and no new lesions.
PR was defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters), no progression in non-target lesions, and no new lesions.
Time of response was calculated by Kaplan-Meier estimates separately for brain, other sites (extracranial) and whole body.
|
Baseline, Week 4, Week 8 and thereafter every 8th week until progressive disease, unacceptable toxicity, consent withdrawal, death or other reasons deemed by the investigator (up to 16 months)
|
Duration of Stable Disease (SD) by Disease Site
Time Frame: Baseline, Week 4, Week 8 and thereafter every 8th week until progressive disease, unacceptable toxicity, consent withdrawal, death or other reasons deemed by the investigator (up to 16 months)
|
Duration of SD was defined as the time between the first documented date of SD and date of PD or death from any cause.
SD was defined (according to RECIST version 1.1) as neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters while on study.
PR was defined as at least a 30% decrease in the sum of diameters of target lesions (taking as reference the baseline sum diameters), no progression in non-target lesions, and no new lesions.
PD was defined as at least 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study and absolute increase of at least 5 mm, progression of existing non-target lesions, or presence of new lesions.
Duration of SD was calculated by Kaplan-Meier estimates separately for brain, other sites (extracranial) and whole body.
|
Baseline, Week 4, Week 8 and thereafter every 8th week until progressive disease, unacceptable toxicity, consent withdrawal, death or other reasons deemed by the investigator (up to 16 months)
|
Time to New Lesion by Disease Site
Time Frame: Baseline, Week 4, Week 8 and thereafter every eighth week until progressive disease, unacceptable toxicity, consent withdrawal, death or other reasons deemed by the investigator (up to 16 months)
|
Time to new lesions was defined as the interval between the date of first treatment and the date of first documentation of new lesions.
Time to new lesion was calculated by Kaplan-Meier estimates separately for brain, other sites (extracranial) and whole body.
|
Baseline, Week 4, Week 8 and thereafter every eighth week until progressive disease, unacceptable toxicity, consent withdrawal, death or other reasons deemed by the investigator (up to 16 months)
|
Percentage of Participants With Disease Progression or Death by Disease Site
Time Frame: Baseline, Week 4, Week 8 and thereafter every 8th week until progressive disease, unacceptable toxicity, consent withdrawal, death or other reasons deemed by the investigator (up to 16 months)
|
Disease progression (according to RECIST version 1.1) was defined as at least 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study or absolute increase and at least 5 mm, progression of existing non-target lesions, or presence of new lesions.
Percentage of participants with disease progression by brain, other sites (extracranial) and whole body are reported.
|
Baseline, Week 4, Week 8 and thereafter every 8th week until progressive disease, unacceptable toxicity, consent withdrawal, death or other reasons deemed by the investigator (up to 16 months)
|
Progression Free Survival (PFS)
Time Frame: Baseline, Week 4, Week 8 and thereafter every eighth week until progressive disease, unacceptable toxicity, consent withdrawal, death or other reasons deemed by the investigator (up to 16 months)
|
PFS was defined as the time interval between the date of the first treatment and the date of progression or death from any cause, whichever occurred first.
Disease progression (according to RECIST version 1.1) was defined as at least 20% increase in the sum of diameters of target lesions compared to smallest sum of diameters on-study or absolute increase and at least 5 mm, progression of existing non-target lesions, or presence of new lesions.
PFS was calculated by Kaplan-Meier estimates separately for brain, other sites (extracranial) and whole body.
|
Baseline, Week 4, Week 8 and thereafter every eighth week until progressive disease, unacceptable toxicity, consent withdrawal, death or other reasons deemed by the investigator (up to 16 months)
|
Percentage of Participants Who Died
Time Frame: Baseline up to end of the study and every 3 months during follow-up (up to 16 months)
|
Percentage of participants who died due to any reason are reported.
|
Baseline up to end of the study and every 3 months during follow-up (up to 16 months)
|
Overall Survival (OS)
Time Frame: From start of treatment up to end of the study and every 3 months during follow up (up to 16 months)
|
OS was defined as the time from the date of first treatment to the date of death, regardless of the cause of death.
Participants who discontinued the study treatment for any reason other than withdrawal of consent were continued to be followed for survival.
The end of study occurred when all participants had been followed for a period of 6 months, had died, withdrawn consent or were lost to follow-up, whichever occurred first.
OS was calculated by Kaplan-Meier estimates.
|
From start of treatment up to end of the study and every 3 months during follow up (up to 16 months)
|
Percentage of Participants With Improvement in Total Daily Dose of Corticosteroids
Time Frame: Baseline, every week during the first 8 weeks and every second week thereafter up to last dose (0.1 to 11.3 months) plus 28 days
|
An improvement in corticosteroid dose was defined as a dose reduction of at least 33% of baseline dose for at least 28 days or stopping use completely.
Percentage of participants and 95% Clopper-Pearson CI are reported.
|
Baseline, every week during the first 8 weeks and every second week thereafter up to last dose (0.1 to 11.3 months) plus 28 days
|
Percentage of Participants With Improvement in Total Daily Dose of Narcotic Pain Analgesic
Time Frame: Baseline, every week during the first 8 weeks and every second week thereafter up to last dose (0.1 to 11.3 months) plus 28 days
|
An improvement in narcotic pain analgesics was defined as a dose reduction of at least 33% of baseline dose for at least 28 days or stopping use completely.
|
Baseline, every week during the first 8 weeks and every second week thereafter up to last dose (0.1 to 11.3 months) plus 28 days
|
Percentage of Participants With Improvement in Visual Analog Scale (VAS) Assessment of Pain
Time Frame: Baseline; Day 1 of Cycles 2-8 (28-day cycle) and at the end of study visit (up to 16 months)
|
VAS is a measure of pain intensity.
The participant was asked to mark on a 100 mm line where their pain level was on the day they completed the scale.
The beginning of the line represented no pain and the end of the line represented maximum pain.
Total score ranged from 0 - 100.
Reported values are decrease in VAS of greater than (>) 20 mm or >30 mm from baseline.
|
Baseline; Day 1 of Cycles 2-8 (28-day cycle) and at the end of study visit (up to 16 months)
|
Percentage of Participants With Improvement in Physician's Assessment of Global Performance Status
Time Frame: Baseline, Day 1 of every 28-day cycle, at end of study and at the 28-day follow-up visit (up to 16 months)
|
Physician's Assessment of Global Performance Status was assessed on 7 point scale (1- Very much better, 2-Much better, 3-A little better, 4-No change, 5-A little worse, 6-Much worse, 7- Very much worse).
An improvement was classed as a difference from baseline of at least -1 point.
Percentage of participants with 95% Clopper-Pearson CI were reported for participants with improvement in Physician's Assessment of Global Performance Status at any visit.
|
Baseline, Day 1 of every 28-day cycle, at end of study and at the 28-day follow-up visit (up to 16 months)
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
November 22, 2010
Primary Completion (Actual)
March 14, 2012
Study Completion (Actual)
March 14, 2012
Study Registration Dates
First Submitted
December 2, 2010
First Submitted That Met QC Criteria
December 2, 2010
First Posted (Estimate)
December 3, 2010
Study Record Updates
Last Update Posted (Actual)
July 31, 2017
Last Update Submitted That Met QC Criteria
June 26, 2017
Last Verified
June 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neoplasms by Histologic Type
- Neoplasms
- Neoplasms by Site
- Neuroectodermal Tumors
- Neoplasms, Germ Cell and Embryonal
- Neoplasms, Nerve Tissue
- Central Nervous System Neoplasms
- Nervous System Neoplasms
- Neuroendocrine Tumors
- Nevi and Melanomas
- Brain Neoplasms
- Melanoma
Other Study ID Numbers
- MO25653
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Malignant Melanoma
-
National Cancer Institute (NCI)TerminatedRecurrent Melanoma | Stage IV Melanoma | Acral Lentiginous Malignant Melanoma | Lentigo Maligna Malignant Melanoma | Nodular Malignant Melanoma | Solar Radiation-related Skin Melanoma | Superficial Spreading Malignant MelanomaUnited States
-
Grupo Español Multidisciplinar de MelanomaGlaxoSmithKlineCompletedMalignant Melanoma Stage IV | Malignant Melanoma Stage IIIcSpain
-
Centre Hospitalier Universitaire de NiceUnknownMalignant Melanoma Stage III | Malignant Melanoma Stage IV
-
Hoffmann-La RocheCompletedMalignant Melanoma, CancerHungary
-
Hoffmann-La RocheCompletedMalignant Melanoma, NeoplasmsUnited States, South Africa, Croatia, Brazil, Egypt
-
Lynn E. Spitler, MDGenentech, Inc.; Celgene CorporationCompletedMetastatic Malignant MelanomaUnited States
-
National Cancer Institute (NCI)GlaxoSmithKline; Novartis PharmaceuticalsActive, not recruitingHematopoietic and Lymphoid Cell Neoplasm | Metastatic Melanoma | Stage IV Cutaneous Melanoma AJCC v6 and v7 | Locally Advanced Malignant Solid Neoplasm | Unresectable Malignant Solid Neoplasm | Locally Advanced Melanoma | Metastatic Malignant Solid Neoplasm | Stage IIIC Cutaneous Melanoma AJCC v7 | Unresectable...United States
-
Hoffmann-La RocheCompletedMalignant Melanoma, NeoplasmsKorea, Republic of, Brazil, United States, Canada, Cyprus
-
Hoffmann-La RocheCompletedMalignant Melanoma, NeoplasmsSpain, New Zealand, Hungary, Serbia, Germany, Portugal, Netherlands, Greece, Australia
-
Steinar AamdalTerminatedMetastatic Malignant MelanomaNorway
Clinical Trials on RO5185426
-
Hoffmann-La RocheCompleted
-
Hoffmann-La RocheCompletedMalignant MelanomaUnited States, Australia
-
Hoffmann-La RocheCompletedA Pharmacokinetic and Metabolism Study of 14C-labeled RO5185426 on Patients With Metastatic MelanomaMalignant MelanomaSwitzerland
-
Hoffmann-La RocheCompleted
-
National Cancer Institute (NCI)TerminatedUnspecified Adult Solid Tumor, Protocol Specific | Recurrent Melanoma | Stage IV Melanoma | Stage IIIA Melanoma | Stage IIIB Melanoma | Stage IIIC MelanomaUnited States
-
National Cancer Institute (NCI)Active, not recruitingSoft Tissue Sarcoma | Osteosarcoma | Ewing Sarcoma | Malignant Glioma | Ependymoma | Rhabdoid Tumor | Advanced Malignant Solid Neoplasm | Refractory Malignant Solid Neoplasm | Rhabdomyosarcoma | Recurrent Malignant Solid Neoplasm | Recurrent Neuroblastoma | Refractory Neuroblastoma | Refractory Non-Hodgkin Lymphoma and other conditionsUnited States, Puerto Rico
-
Hoffmann-La RocheCompletedMelanomaUnited States, Israel, Italy, Spain, Belgium, United Kingdom, Austria, Czechia, France, Netherlands, New Zealand, Russian Federation, Australia, Canada, Croatia, Portugal, Germany, Ukraine, Switzerland, Argentina, Brazil, Ireland, N... and more
-
Hoffmann-La RocheCompletedNeoplasmsUnited Kingdom, Israel, United States, Russian Federation, Australia, Greece, Turkey
-
University of ArkansasWithdrawnMultiple MyelomaUnited States
-
Hoffmann-La RocheCompletedMalignant MelanomaCanada, Spain, United Kingdom, Hungary, Australia, Austria, Belgium, Ecuador, Estonia, Finland, Ireland, Italy, Korea, Republic of, Mexico, Netherlands, Portugal, Slovenia, Sweden, Turkey, Brazil, India, Germany, Bosnia and Herzegovina and more